Belcher G
Cardiovascular Clinical Research Unit, Schering Health Care, West Sussex, U.K.
Agents Actions Suppl. 1992;37:354-60. doi: 10.1007/978-3-0348-7262-1_48.
The effects of i.v. iloprost given for 14-28 days on six month outcome in patients with severe inoperable lower limb ischaemia were investigated in a double-blind placebo controlled study. More iloprost patients (64%) survived with a viable limb than placebo patients (42%). Iloprost improved prognosis in all subgroups of patients, but patients with lower presenting ankle Doppler pressures had a worse outcome than patients with higher pressures.
在一项双盲安慰剂对照研究中，调查了静脉注射伊洛前列素14至28天对严重不可手术的下肢缺血患者六个月预后的影响。与安慰剂组患者（42%）相比，更多接受伊洛前列素治疗的患者（64%）存活且肢体存活。伊洛前列素改善了所有患者亚组的预后，但初始踝部多普勒压力较低的患者比压力较高的患者预后更差。
